Since New Year 2018, CSL limited [ASX:CSL] shares have been plotting along nicely.
Despite a small dip in share price in today’s market — as shares are now trading at $197.20 apiece, down 0.72% at the time of writing — investors shouldn’t be too worried. Just think, at the start of this year on Tuesday 2 January, CSL shares were only trading at 140.55. That’s an increase of 40.93% in as little as seven months.
Compelling share price forecasts for CSL
The company has named some key variables that could be underlining their success. Which they claim could be having a significant impact on guidance.
After a severe northern Hemisphere influenza season, CSL’s acquirement of the Novartis Influenza vaccine business — now integrated into Seqirus — is performing well.
CSL’s Chief Executive Officer and Managing Director said:
‘I am pleased to report an improved Company outlook for the financial year, underpinned by a confluence of positive outcomes as we work to deliver on our strategy.’
Investors must also consider share price shifting on account of changes in healthcare regulations and reimbursement policies, as well as royalties and sales of CSL’s influenza and plasma companies.
CSL lifts profit guidance
The take away for CSL is that this year’s provided guidance has an expected net profit (after tax for FY18) to be approximately US$1,550–1,600 million at constant currency.
For Money Morning
PS: Thinking of investing? You’ll find over 2,000 stocks listed on the ASX and on any given day a bunch will rise or fall. It’s near impossible to monitor these on your own. Our analyst Sam Volkering has picked out four Aussie stocks he believes could be top performers in 2018. Check out his free report ‘The Four Best ASX Stocks for 2018’.